+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Effect of androgen deprivation therapy on bone mineral density in prostate cancer patients



Effect of androgen deprivation therapy on bone mineral density in prostate cancer patients



Asian Journal of Andrology 6(1): 75-77



Aim: To evaluate the effect of androgen deprivation therapy (ADT) on bone mineral density (BMD) in prostate cancer patients. Methods: Forty-nine prostate cancer patients with their BMD determined were divided into two groups: the non-treated group included 21 patients before the commencement of ADT and the treated group, 28 patients, who had received ADT for more than 1 year. BMD was measured by dual energy X-ray absorptiometry (DEXA) in the lumbar spine (L2-4) and femoral neck. Results: Thirteen (62 %) non-treated and 23 (82 %) treated patients fulfilled the BMD criteria for osteopenia or osteoporosis. Z scores for age-matched control in lumbar spine and femoral neck were -0.9 +- 0.7 and -0.6 +- 0.5, respectively, in the treated group, and -1.8 +- 1.1 and -1.6 +- 1.0, respectively, in the non-treated group, the differences between the two groups were highly significant (P<0.01). Conclusion: Prostate cancer patients who received ADT for more than 1 year had a significantly lower BMD in the lumbar spine and femoral neck than those before the beginning of ADT.

(PDF emailed within 1 workday: $29.90)

Accession: 011991796

Download citation: RISBibTeXText

PMID: 15064839


Related references

Effect of Androgen-deprivation Therapy on Bone Mineral Density in Japanese Patients with Prostate Cancer. In Vivo 32(2): 409-412, 2018

Androgen deprivation therapy in patients with prostate cancer and changes in bone mineral density. Journal of Bone & Mineral Research 16(Suppl 1): S243, September, 2001

Changes in bone mineral density in patients with prostate cancer treated with androgen deprivation therapy. Collegium Antropologicum 29(2): 589-591, 2006

Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy. Endocrine-Related Cancer 15(4): 943-952, 2008

Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. Urology 75(5): 1131-1137, 2010

Effect of Diphosphonates on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer. Clinical Genitourinary Cancer, 2018

Bone mineral density, pathological fractures and bisphosphonate therapy in prostate cancer patients on androgen deprivation therapy. Endocrine Regulations 45(4): 199-204, 2012

Self-reported exercise and bone mineral density in prostate cancer patients receiving androgen deprivation therapy. Journal of the American Association of Nurse Practitioners 26(1): 40-48, 2015

Bone mineral density in prostate cancer patients treated with androgen deprivation therapy; Preliminary results. European Urology Supplements 15(13): E1630-E1631, 2016

Evaluation of Bone Turnover / Quality Markers and Bone Mineral Density in Prostate Cancer Patients Receiving Androgen Deprivation Therapy with or without Denosumab. Anticancer Research 37(7): 3667-3671, 2017

Decrease of bone mineral density in Japanese patients with non-metastatic prostate cancer treated with androgen deprivation therapy. Journal of Bone and Mineral Metabolism, 2018

Effect of Androgen Deprivation Therapy on Bone Mineral Density in a Prostate Cancer Cohort in New Zealand: A Pilot Study. Clinical Medicine Insights. Oncology 11: 1179554917733449-1179554917733449, 2017

Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. Journal of Urology 176(3): 972-8; Discussion 978, 2006

Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy. Urology 70(1): 122-126, 2007

Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. Journal of Urology 167(6): 2361-2367, June, 2002